Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel

<table>Median PSA (with minimum and maximum values) in 18 out of 27 responding patients who showed a PSA surge within the first 3 months of treatment with weekly D + biweekly Bev.</table>

Prostate Cancer

fig1

Figure 1

Figure 1: Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel 